IL290884B2 - Particles attached to the peptide - Google Patents

Particles attached to the peptide

Info

Publication number
IL290884B2
IL290884B2 IL290884A IL29088422A IL290884B2 IL 290884 B2 IL290884 B2 IL 290884B2 IL 290884 A IL290884 A IL 290884A IL 29088422 A IL29088422 A IL 29088422A IL 290884 B2 IL290884 B2 IL 290884B2
Authority
IL
Israel
Prior art keywords
peptide conjugated
conjugated particles
particles
peptide
conjugated
Prior art date
Application number
IL290884A
Other languages
English (en)
Hebrew (he)
Other versions
IL290884A (en
IL290884B1 (en
Original Assignee
Univ Northwestern
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Northwestern filed Critical Univ Northwestern
Publication of IL290884A publication Critical patent/IL290884A/en
Publication of IL290884B1 publication Critical patent/IL290884B1/en
Publication of IL290884B2 publication Critical patent/IL290884B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
    • A61K47/6937—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol the polymer being PLGA, PLA or polyglycolic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
IL290884A 2012-06-21 2013-06-21 Particles attached to the peptide IL290884B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261662687P 2012-06-21 2012-06-21
PCT/US2013/047079 WO2013192532A2 (en) 2012-06-21 2013-06-21 Peptide conjugated particles

Publications (3)

Publication Number Publication Date
IL290884A IL290884A (en) 2022-04-01
IL290884B1 IL290884B1 (en) 2025-12-01
IL290884B2 true IL290884B2 (en) 2026-04-01

Family

ID=49769721

Family Applications (4)

Application Number Title Priority Date Filing Date
IL290884A IL290884B2 (en) 2012-06-21 2013-06-21 Particles attached to the peptide
IL324444A IL324444A (en) 2012-06-21 2013-06-21 Particles attached to the peptide
IL236191A IL236191B (en) 2012-06-21 2014-12-11 Peptide conjugated particles
IL266880A IL266880B (en) 2012-06-21 2019-05-26 Particles are attached to the peptide

Family Applications After (3)

Application Number Title Priority Date Filing Date
IL324444A IL324444A (en) 2012-06-21 2013-06-21 Particles attached to the peptide
IL236191A IL236191B (en) 2012-06-21 2014-12-11 Peptide conjugated particles
IL266880A IL266880B (en) 2012-06-21 2019-05-26 Particles are attached to the peptide

Country Status (19)

Country Link
US (5) US10201596B2 (pl)
EP (2) EP3607973A1 (pl)
JP (5) JP6557140B2 (pl)
KR (5) KR20220166879A (pl)
CN (2) CN110064049B (pl)
AU (5) AU2013278056B2 (pl)
BR (1) BR112014032207B1 (pl)
CA (2) CA2876495C (pl)
DK (1) DK2863942T3 (pl)
ES (1) ES2738481T3 (pl)
HR (1) HRP20191178T1 (pl)
IL (4) IL290884B2 (pl)
MX (1) MX363889B (pl)
PL (1) PL2863942T3 (pl)
PT (1) PT2863942T (pl)
RU (1) RU2669346C2 (pl)
TR (1) TR201909998T4 (pl)
WO (1) WO2013192532A2 (pl)
ZA (1) ZA201409305B (pl)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011325966B2 (en) 2010-11-12 2016-09-29 Oncour Pharma, Inc. Modified immune-modulating particles
US9597385B2 (en) 2012-04-23 2017-03-21 Allertein Therapeutics, Llc Nanoparticles for treatment of allergy
CN110064049B (zh) 2012-06-21 2024-02-09 西北大学 肽缀合粒子
US11439594B2 (en) 2012-12-04 2022-09-13 Phosphorex, Inc. Microparticles and nanoparticles having negative surface charges
EP3494966B1 (en) 2013-03-13 2024-04-03 onCOUR Pharma, Inc. Immune-modifying particles for the treatment of inflammation
KR102233251B1 (ko) 2013-04-03 2021-03-26 엔-폴드 엘엘씨 신규 나노입자 조성물
KR20160042079A (ko) * 2013-08-13 2016-04-18 노쓰웨스턴유니버시티 펩티드-접합된 입자
JP7194593B2 (ja) * 2015-12-23 2022-12-22 クール ファーマシューティカルズ ディベロップメント カンパニー インコーポレイテッド 共有ポリマー抗原コンジュゲート化粒子
EP3400069A4 (en) * 2016-01-04 2019-09-25 Cour Pharmaceuticals Development Company Inc. Particles for the Encapsulation of Fusion Proteins with Bundled Epitopes
GB2550586A (en) 2016-05-23 2017-11-29 A-Fax Ltd Racking protection device
US20210115378A1 (en) * 2018-05-09 2021-04-22 Yale University Compositions and systems for ex vivo cell modulation and methods of use thereof
JP2021523151A (ja) * 2018-05-11 2021-09-02 ホスホレックス、インコーポレイテッド 負の表面電荷を有するマイクロ粒子及びナノ粒子
US20210186880A1 (en) * 2018-08-03 2021-06-24 Brown University Oral formulations with increased uptake
WO2021231898A2 (en) * 2020-05-14 2021-11-18 Op-T Llc Nanoparticle compositions and uses thereof
WO2022015518A1 (en) * 2020-07-14 2022-01-20 Corning Incorporated Rapidly dissolving cell culture media powder and methods of making the same
WO2023070104A1 (en) 2021-10-21 2023-04-27 Cour Pharmaceuticals Development Company Inc. Treatment of primary biliary cholangitis (pbc) with tolerizing nanoparticles
AU2023314797A1 (en) 2022-07-29 2024-12-12 Repertoire Immune Medicines, Inc. T cell epitopes associated with type 1 diabetes
KR20260016937A (ko) 2023-05-23 2026-02-04 코어 파마슈티칼스 디벨롭먼트 컴퍼니 인크. 원발성 담즙성 담관염의 치료를 위한 관용화 나노입자의 제조
IL324854A (en) 2023-05-25 2026-01-01 Cour Pharmaceuticals Dev Company Inc Treatment of type 1 diabetes (t1d) with tolerizing nanoparticles
WO2025072849A1 (en) 2023-09-29 2025-04-03 Repertoire Immune Medicines, Inc. Mhc-presentable peptides associated with type 1 diabetes
WO2026019942A2 (en) 2024-07-16 2026-01-22 Cour Pharmaceuticals Development Company Inc. Tolerizing immune modifying nanoparticles for treatment of narcolepsy

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7829113B2 (en) * 2005-03-10 2010-11-09 Mebiopharm Co., Ltd. Liposome compositions
WO2011133617A1 (en) * 2010-04-23 2011-10-27 The Board Of Trustees Of The University Of Illinois Nano-hybrid delivery system for sequential utilization of passive and active targeting
WO2011150573A1 (en) * 2010-06-04 2011-12-08 Tongji University Copolymer of pyrene and pyrrole and method of producing the copolymer

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4565696A (en) * 1983-08-03 1986-01-21 The Regents Of The University Of California Production of immunogens by antigen conjugation to liposomes
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
HU220357B (hu) 1992-02-28 2001-12-28 Autoimmune Inc. Eljárás és készítmények autoimmun betegségek kezelésére bystander antigén alkalmazásával
FR2695563B1 (fr) 1992-09-11 1994-12-02 Pasteur Institut Microparticules portant des antigènes et leur utilisation pour l'induction de réponses humorales ou cellulaires.
US6004763A (en) 1992-09-11 1999-12-21 Institut Pasteur Antigen-carrying microparticles and their use in the induction of humoral or cellular responses
JPH06157592A (ja) 1992-11-24 1994-06-03 Hitachi Chem Co Ltd ペプチドもしくはその誘導体、それらとタンパク質との結合体、及びこれらを免疫源とする抗エンドセリン−１抗体の製造方法
EP0705108A4 (en) 1993-06-02 1997-08-06 Tvw Telethon Inst Child Health USE OF CRYPTIC PEPTIDES FOR INDUCTION IMMUNOLOGICAL TOLERANCE
US5804201A (en) 1996-03-11 1998-09-08 The Rockefeller University Immunomodulatory peptides of vespid antigen 5
ATE249491T1 (de) 1997-03-31 2003-09-15 Univ Michigan Offenporige bioabbaubare matrize
US7427602B1 (en) 1998-05-13 2008-09-23 The Regents Of The University Of Michigan Sustained DNA delivery from structural matrices
EP1212086B8 (en) 1999-08-18 2008-01-02 Industry-Academic Cooperation Foundation, The Catholic University of Korea Immunological tolerance-induction agent
US20020131960A1 (en) 2000-06-02 2002-09-19 Michel Sadelain Artificial antigen presenting cells and methods of use thereof
AU2001295503A1 (en) 2000-08-22 2002-03-04 Micromet Ag Composition for the elimination of autoreactive b-cells
US7029697B2 (en) 2001-02-14 2006-04-18 Northwestern University Controlled surface-associated delivery of genes and oligonucleotides
US6890556B1 (en) 2001-02-14 2005-05-10 Northwestern University Controlled surface-associated delivery of genes and oligonucleotides
EP1438323A4 (en) * 2001-10-03 2007-08-01 Novartis Vaccines & Diagnostic ADJUVOUS MENINGOCOCCUS COMPOSITIONS
JP2005511629A (ja) 2001-11-20 2005-04-28 アドバンスト インハレーション リサーチ，インコーポレイテッド 持続作用生成物送達用組成物
DK1487485T3 (da) 2002-03-19 2011-03-14 Powderject Res Ltd Imidazoquinolinadjuvanser til DNA-vacciner
WO2003092654A1 (en) 2002-05-02 2003-11-13 President And Fellows Of Harvard College Formulations limiting spread of pulmonary infections
DE60334474D1 (de) 2002-07-12 2010-11-18 Univ Johns Hopkins Reagenzien und verfahren zum eingriff in einzigartige klonotype lymphozyten-rezeptoren
US7465463B2 (en) 2002-09-04 2008-12-16 Polyheal, Ltd. Compositions comprising microspheres with anti-inflammatory properties for healing of ocular tissues
US20060189554A1 (en) * 2002-09-24 2006-08-24 Russell Mumper Nanoparticle-Based vaccine delivery system containing adjuvant
WO2005000272A1 (en) 2003-06-04 2005-01-06 Isis Pharmaceuticals, Inc. Long-circulating liposomal compositions
WO2005015160A2 (en) 2003-08-07 2005-02-17 The Children's Hospital Of Philadelphia Functionalized polymeric colloids
WO2005019429A2 (en) 2003-08-22 2005-03-03 Potentia Pharmaceuticals, Inc. Compositions and methods for enhancing phagocytosis or phagocyte activity
US9149440B2 (en) 2003-09-02 2015-10-06 University Of South Florida Nanoparticles for drug-delivery
US20070275007A1 (en) 2003-11-05 2007-11-29 The Government Of The United States Of America, Represented By The Secretary Of Health And Human S Carbohydrate Antigen-Nanoparticle Conjugates and Uses Thereof as Antimetastatic Agents in Treating Cancer
EP1547581A1 (en) * 2003-12-23 2005-06-29 Vectron Therapeutics AG Liposomal vaccine for the treatment of human hematological malignancies
ES2246695B1 (es) 2004-04-29 2007-05-01 Instituto Cientifico Y Tecnologico De Navarra, S.A. Composicion estimuladora de la respuesta inmunitaria que comprende nanoparticulas a base de un copolimero de metil vinil eter y anhidrido maleico.
US7846466B2 (en) 2004-06-10 2010-12-07 Northwestern University Biodegradable scaffolds and uses thereof
WO2006080951A2 (en) 2004-07-01 2006-08-03 Yale University Targeted and high density drug loaded polymeric materials
CN102016814B (zh) 2005-06-17 2013-10-23 北卡罗来纳大学查珀尔希尔分校 纳米粒子制备方法、系统及材料
CN101213226A (zh) 2005-07-01 2008-07-02 霍夫曼-拉罗奇有限公司 羧基化胶乳粒子
WO2007008755A2 (en) 2005-07-08 2007-01-18 The Board Of Regents, The University Of Texas System Surface functionalization of polymeric materials
GB0514262D0 (en) 2005-07-12 2005-08-17 Renovo Ltd Promotion of epithelial regeneration
US20070041934A1 (en) 2005-08-12 2007-02-22 Regents Of The University Of Michigan Dendrimer based compositions and methods of using the same
WO2007087341A2 (en) 2006-01-25 2007-08-02 The Board Of Trustees Of The University Of Illinois Tolerogenic biodegradable artificial antigen presenting system
US20090304726A1 (en) 2006-02-15 2009-12-10 Ramot At Tel Aviv University Ltd. Viral display vehicles for treating multiple sclerosis
US8431160B2 (en) * 2006-02-24 2013-04-30 Novartis Ag Microparticles containing biodegradable polymer and cationic polysaccharide for use in immunogenic compositions
US20090325931A1 (en) 2006-07-28 2009-12-31 University Court Of The University Of Edinburgh Use of cdk inhibitors for the treatment of granulocyte mediated disorders
AU2007306936B2 (en) 2006-10-12 2014-02-06 The University Of Queensland Compositions and methods for modulating immune responses
US20090214474A1 (en) 2006-11-01 2009-08-27 Barbara Brooke Jennings Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
RU2481125C2 (ru) 2006-12-18 2013-05-10 Колороббия Италия С.П.А. Магнитные наночастицы для применения при гипертермии, их приготовление и применение в магнитных системах для фармакологического использования
CN101678090B (zh) 2007-03-07 2012-04-11 乌第有限合伙公司 用于预防和治疗自身免疫病的组合物和方法
US20080311140A1 (en) 2007-05-29 2008-12-18 Baylor College Of Medicine Antigen specific immunosuppression by dendritic cell therapy
CN104740624B (zh) 2007-09-18 2018-04-24 武田疫苗股份有限公司 赋予针对诺如病毒的保护性免疫应答的疫苗
JP2011500569A (ja) * 2007-10-12 2011-01-06 マサチューセッツ インスティテュート オブ テクノロジー ワクチンナノテクノロジー
US20110014292A1 (en) 2007-10-15 2011-01-20 Cooperative Research Centre For Asthma method of prophylaxis and agents for use therein
WO2009052561A1 (en) 2007-10-22 2009-04-30 The Walter And Eliza Hall Institute Of Medical Research Compositions and methods for manipulating an immune response
EP2057998A1 (en) 2007-10-31 2009-05-13 Universitätsklinikum Hamburg-Eppendorf Use of modified cells for the treatment of multiple sclerosis
US20090123509A1 (en) 2007-11-08 2009-05-14 Cory Berkland Biodegradable Colloidal Gels as Moldable Tissue Engineering Scaffolds
US20090238879A1 (en) 2008-01-24 2009-09-24 Northwestern University Delivery scaffolds and related methods of use
US9669057B2 (en) 2008-04-25 2017-06-06 Duke University Regulatory B cells and their uses
US20110206773A1 (en) 2008-05-20 2011-08-25 Yale University Sustained delivery of drugs from biodegradable polymeric microparticles
EP2123261A1 (en) 2008-05-20 2009-11-25 Stallergenes S.A. Mucoadhesive particulate formulation for inducing antigen-specific immune tolerance
US8323696B2 (en) 2008-08-29 2012-12-04 Ecole Polytechnique Federale De Lausanne Nanoparticles for immunotherapy
WO2010037142A1 (en) 2008-09-29 2010-04-01 The Corporation Of Mercer University Nanospheres encapsulating bioactive material and method for formulation of nanospheres
EP2352568B1 (en) 2008-10-02 2017-11-29 University of Pittsburgh - Of the Commonwealth System of Higher Education Administration of an adsorbent polymer for treatment of systemic inflammation
HUE027237T2 (en) 2008-11-30 2016-10-28 Immusant Inc Compositions and methods for treatment of celiac disease
EP2376115A4 (en) 2008-12-11 2013-07-03 Univ Alberta METHOD AND SYSTEM FOR INDUCING IMMUNOLOGICAL TOLERANCE IN RESELLERS
TW201039843A (en) 2009-01-20 2010-11-16 Myelin Repair Foundation Inc Compositions and methods for induced tolerance
EP2255831A1 (en) 2009-05-25 2010-12-01 Institut Pasteur Liposome based diepitope constructs
BRPI1012036A2 (pt) 2009-05-27 2017-10-10 Selecta Biosciences Inc nanocarreadores que possuem componentes com diferentes taxas de liberação
WO2011031441A1 (en) 2009-08-28 2011-03-17 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Therapy with a chimeric molecule and a pro-apoptotic agent
US20110135744A1 (en) 2009-12-03 2011-06-09 The Regents Of The University Of California Nanoparticle Based Therapy for Dispersing Mucin
EP2538969A4 (en) 2010-02-22 2013-11-27 Liquidia Technologies Inc VACCINES FROM POLYSACCHARIDE PARTICLES
WO2011119262A1 (en) 2010-03-26 2011-09-29 Cerulean Pharma Inc. Methods and systems for generating nanoparticles
US9408906B2 (en) 2010-06-04 2016-08-09 Flow Pharma, Inc. Peptide particle formulation
AU2011272941B2 (en) 2010-06-30 2014-05-29 Compugen Ltd. C10RF32 for the treatment of multiple sclerosis, rheumatoid arthritis and other autoimmune disorders
US9522183B2 (en) 2010-07-31 2016-12-20 The Scripps Research Institute Compositions and methods for inducing immune tolerance
EP2600878A4 (en) 2010-08-04 2014-06-11 Univ Duke REGULATORY B-CELLS AND ITS USES
AU2011325966B2 (en) 2010-11-12 2016-09-29 Oncour Pharma, Inc. Modified immune-modulating particles
WO2012071014A1 (en) * 2010-11-24 2012-05-31 Nanyang Technological University Method for coating particles with calcium phosphate and particles, microparticles and nanoparticles formed thereof
US10064406B2 (en) 2011-01-06 2018-09-04 Cytosorbents Corporation Polymeric sorbent for removal of impurities from whole blood and blood products
CA2825016C (en) 2011-01-24 2021-02-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Nanoparticles for dermal and systemic delivery of drugs
MX374963B (es) 2011-04-29 2025-03-06 Selecta Biosciences Inc Nanoportadores sintéticos tolerogénicos para reducir las respuestas de anticuerpos.
KR20140050698A (ko) 2011-07-29 2014-04-29 셀렉타 바이오사이언시즈, 인크. 체액성 및 세포독성 t 림프구(ctl) 면역 반응을 발생시키는 합성 나노운반체
WO2013036301A1 (en) 2011-09-06 2013-03-14 Selecta Biosciences, Inc. Induced tolerogenic dendritic cells for inducing regulatory b cells
WO2013115965A1 (en) 2012-01-31 2013-08-08 Cerulean Pharma Inc. Polymer-agent conjugates, particles, compositions, and related methods of use
CN110064049B (zh) 2012-06-21 2024-02-09 西北大学 肽缀合粒子
EP3494966B1 (en) 2013-03-13 2024-04-03 onCOUR Pharma, Inc. Immune-modifying particles for the treatment of inflammation
KR20160042079A (ko) 2013-08-13 2016-04-18 노쓰웨스턴유니버시티 펩티드-접합된 입자

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7829113B2 (en) * 2005-03-10 2010-11-09 Mebiopharm Co., Ltd. Liposome compositions
WO2011133617A1 (en) * 2010-04-23 2011-10-27 The Board Of Trustees Of The University Of Illinois Nano-hybrid delivery system for sequential utilization of passive and active targeting
WO2011150573A1 (en) * 2010-06-04 2011-12-08 Tongji University Copolymer of pyrene and pyrrole and method of producing the copolymer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BATTAGLIA, MANUELA, ET AL., RAPAMYCIN AND INTERLEUKIN-10 TREATMENT INDUCES T REGULATORY TYPE 1 CELLS THAT MEDIATE ANTIGEN-SPECIFIC TRANSPLANTATION TOLERANCE., 1 January 2006 (2006-01-01) *
CHAUHAN, ABHAY S., ET AL., UNEXPECTED IN VIVO ANTI-INFLAMMATORY ACTIVITY OBSERVED FOR SIMPLE, SURFACE FUNCTIONALIZED POLY (AMIDOAMINE) DENDRIMERS., 6 April 2009 (2009-04-06) *
NYGAARD, UNNI CECILIE, AUDUN AASE, AND MARTINUS L?VIK., THE ALLERGY ADJUVANT EFFECT OF PARTICLES–GENETIC FACTORS INFLUENCE ANTIBODY AND CYTOKINE RESPONSES., 21 June 2005 (2005-06-21) *

Also Published As

Publication number Publication date
MX363889B (es) 2019-04-05
US20250009858A1 (en) 2025-01-09
AU2018236881A1 (en) 2018-10-25
AU2020244453B2 (en) 2025-02-20
AU2013278056A1 (en) 2015-01-22
IL236191B (en) 2019-05-30
DK2863942T3 (da) 2019-07-15
EP2863942A4 (en) 2016-04-27
CA2876495A1 (en) 2013-12-27
MX2014015843A (es) 2016-05-05
PL2863942T3 (pl) 2019-12-31
KR102283760B1 (ko) 2021-08-03
JP7491869B2 (ja) 2024-05-28
CA3211102A1 (en) 2013-12-27
BR112014032207B1 (pt) 2021-07-27
HK1209039A1 (en) 2016-03-24
CN110064049A (zh) 2019-07-30
KR20210096312A (ko) 2021-08-04
US20150209293A1 (en) 2015-07-30
CN104684578A (zh) 2015-06-03
CN110064049B (zh) 2024-02-09
CA2876495C (en) 2023-10-17
US20200330569A1 (en) 2020-10-22
AU2020244453A1 (en) 2020-10-29
EP2863942B1 (en) 2019-04-10
AU2020203884A1 (en) 2020-07-02
JP2023153869A (ja) 2023-10-18
AU2025203403A1 (en) 2025-05-29
IL266880B (en) 2022-04-01
IL324444A (en) 2026-01-01
IL236191A0 (en) 2015-01-29
CN104684578B (zh) 2019-04-19
HRP20191178T1 (hr) 2019-10-04
KR20220166879A (ko) 2022-12-19
JP2021165273A (ja) 2021-10-14
KR102139267B1 (ko) 2020-07-31
ZA201409305B (en) 2019-08-28
AU2018236881B2 (en) 2020-07-02
EP3607973A1 (en) 2020-02-12
AU2013278056B2 (en) 2018-07-05
KR20150032869A (ko) 2015-03-30
US20240082371A1 (en) 2024-03-14
JP2015522569A (ja) 2015-08-06
EP2863942A2 (en) 2015-04-29
KR20250052503A (ko) 2025-04-18
IL290884A (en) 2022-04-01
US20190262441A1 (en) 2019-08-29
JP2025163048A (ja) 2025-10-28
ES2738481T3 (es) 2020-01-23
RU2015101758A (ru) 2016-08-20
JP7210306B2 (ja) 2023-01-23
JP2019142844A (ja) 2019-08-29
JP6557140B2 (ja) 2019-08-07
US11413337B2 (en) 2022-08-16
BR112014032207A2 (pt) 2017-08-01
KR20200091506A (ko) 2020-07-30
IL290884B1 (en) 2025-12-01
US11826407B2 (en) 2023-11-28
IL266880A (en) 2019-07-31
US10201596B2 (en) 2019-02-12
TR201909998T4 (tr) 2019-07-22
PT2863942T (pt) 2019-07-17
WO2013192532A3 (en) 2015-04-02
RU2669346C2 (ru) 2018-10-10
WO2013192532A2 (en) 2013-12-27

Similar Documents

Publication Publication Date Title
IL290884A (en) Particles are attached to the peptide
IL273615B (en) Peptide-conjugated particles
EP2857033A4 (en) PEPTIDE WITH SKIN PERMEATION
SG11201500111VA (en) Peptides and uses thereof
SG11201501646PA (en) Peptides and their uses
GB201111183D0 (en) Peptide
GB201115910D0 (en) Peptides
PL2938353T3 (pl) Peptydy przeciwzapalne
PT2809342T (pt) Péptido bifuncional
EP2867303A4 (en) PARTICLES OF THE SILSESQUIOXANE TYPE
ZA201503127B (en) Peptides
GB201200555D0 (en) Peptide
GB201204868D0 (en) Peptides
GB201218278D0 (en) Translocating peptide
PL2584028T3 (pl) Cząstka
GB201223114D0 (en) Novel peptide
EP2891663A4 (en) PEPTIDE DERIVED FROM PSF1
GB201221414D0 (en) Trans-locating peptide
GB201200624D0 (en) Peptide
GB201200623D0 (en) Peptide
GB201220328D0 (en) Peptides
GB201211740D0 (en) Peptides
GB201207895D0 (en) Peptides
GB201200509D0 (en) Peptides
AU4811P (en) Bidgee Glycine max